DaVita Inc. (NYSE:DVA) Shares Bought by KBC Group NV

KBC Group NV lifted its stake in shares of DaVita Inc. (NYSE:DVA) by 27.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 313,519 shares of the company’s stock after purchasing an additional 67,250 shares during the quarter. KBC Group NV owned about 0.38% of DaVita worth $51,395,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its position in DaVita by 1.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock worth $776,000 after acquiring an additional 70 shares in the last quarter. Wedmont Private Capital lifted its stake in DaVita by 4.4% during the third quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after purchasing an additional 75 shares during the last quarter. Blue Trust Inc. boosted its holdings in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares in the last quarter. First Trust Direct Indexing L.P. grew its position in DaVita by 2.9% in the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock worth $500,000 after buying an additional 86 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of DaVita by 0.3% in the third quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock valued at $6,036,000 after buying an additional 126 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent research reports. Truist Financial lifted their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen raised their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Bank of America boosted their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. Finally, Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $161.80.

Insider Buying and Selling at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The trade was a 36.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 156,086 shares of company stock worth $24,807,161 over the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

DaVita Price Performance

NYSE DVA opened at $154.38 on Friday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The firm has a market capitalization of $12.66 billion, a price-to-earnings ratio of 16.65, a price-to-earnings-growth ratio of 0.89 and a beta of 0.89. The company has a 50 day simple moving average of $157.57 and a 200-day simple moving average of $147.35. DaVita Inc. has a 52-week low of $91.87 and a 52-week high of $168.50.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the previous year, the company earned $2.85 EPS. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.